Publications

First Trimester Down Syndrome Screening with Free Beta hCG

• First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay.
  

  Krantz D, Hallahan T, Ravens R, He K, Cuckle H, Sherwin J, Carmichael J. Prenat Diagn. 2011 Jun 21. doi: 10.1002/pd.2792.

• Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol.
  

  Krantz DA, Hallahan TW, Macri VJ, Macri JN. Prenat Diagn. 2005 Aug;25(8):635-40.

• Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program.
  

  Krantz DA, Hallahan TW, Macri VJ, Macri JN. Prenat Diagn. 2005 Aug;25(8):635-40. PubMed

• First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. First-trimester screening for trisomies 21 and 18.
  

  Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, Platt L, Mahoney M, Johnson A, Hogge WA, Wilson RD, Mohide P, Hershey D, Krantz D, Zachary J, Snijders R, Greene N, Sabbagha R, MacGregor S, Hill L, Gagnon A, Hallahan T, Jackson L; N Engl J Med. 2003 Oct 9;349(15):1405-13. PubMed

• Combined first-trimester versus second-trimester serum screening for Down syndrome: a cost analysis.
  

  Cusick W, Buchanan P, Hallahan TW, Krantz DA, Larsen JW Jr, Macri JN. Am J Obstet Gynecol. 2003 Mar;188(3):745-51. PubMed

• First trimester screening with free beta-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction.
  

  Orlandi F, Rossi C, Allegra A, Krantz D, Hallahan T, Orlandi E, Macri J. Prenat Diagn. 2002 Aug;22(8):718-21. PubMed

• CFirst trimester biochemical screening for Down syndrome: free beta hCG versus intact hCG.
  

  Hallahan T, Krantz D, Orlandi F, Rossi C, Curcio P, Macri S, Larsen J, Buchanan P, Macri J. Prenat Diagn. 2000 Oct;20(10):785-9;discussion 790-1. PubMed

• First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
  

  Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. Obstet Gynecol. 2000 Aug;96(2):207-13. PubMed

• First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
  

  Orlandi F, Damiani G, Hallahan TW, Krantz DA, Macri JN. Ultrasound Obstet Gynecol. 1997 Dec;10(6):381-6. PubMed

• First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A.
  

  Krantz DA, Larsen JW, Buchanan PD, Macri JN. Am J Obstet Gynecol. 1996 Feb;174(2):612-6. PubMed

• Analysis of maternal serum alpha-fetoprotein and free beta human chorionic gonadotrophin in the first trimester: implications for Down's syndrome screening.
  

  E, Aitken DA, Crossley JA, Macri JN, Connor JM. Prenat Diagn. 1995 Jun;15(6):555-65. PubMed

• First trimester biochemical screening for trisomy 21: the role of free beta hCG, alpha fetoprotein and pregnancy associated plasma protein A.
  

  Spencer K, Aitken DA, Crossley JA, McCaw G, Berry E, Anderson R, Connor JM, Macri JN. Ann Clin Biochem. 1994 Sep;31 ( Pt 5):447-54. PubMed

• First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects.
  

  Aitken DA, McCaw G, Crossley JA, Berry E, Connor JM, Spencer K, Macri JN. Prenat Diagn. 1993 Aug;13(8):681-9. PubMed

• First-trimester free beta (hCG) screening for Down syndrome.
  

  Macri JN, Spencer K, Aitken D, Garver K, Buchanan PD, Muller F, Boue A. Prenat Diagn. 1993 Jul;13(7):557-62. PubMed

• First-trimester free beta (hCG) screening for Down syndrome.
  

  Macri JN, Spencer K, Aitken D, Garver K, Buchanan PD, Muller F, Boue A. Prenat Diagn. 1993 Jul;13(7):557-62. PubMed

• Free beta-hCG as first-trimester marker for fetal trisomy.
  

  Spencer K, Macri JN, Aitken DA, Connor JM. Lancet. 1992 Jun 13;339(8807):1480. PubMed

Timing of First Trimester Biochemistry in Down syndrome Screening

• Does timing of biochemistry in first-trimester aneuploidy risk assessment affect the gestational age at prenatal diagnosis and pregnancy termination?
  

  Chasen ST, Krantz D. Prenat Diagn. 2010 Dec;30(12-13):1151-4. PubMed

• First-trimester combined screening: experience with an instant results approach.
  

  Norton ME, Hopkins LM, Pena S, Krantz D, Caughey AB. Am J Obstet Gynecol. 2007 Jun;196(6):606.e1-5; discussion 606.e5. PubMed

NT Quality Control

• Impact of NT credentialing by FMF, NTQR, or both upon screening distributions and performance.
  

  Evans MI, Krantz DA, Hallahan TW, Sherwin J. Ultrasound Obstet Gynecol. 2011 Apr 12. doi: 10.1002/uog.9023. [Epub ahead of print] PubMed

• Undermeasurement of nuchal translucencies: implications for screening.
  

  Evans MI, Krantz DA, Hallahan TW, Sherwin JE. Obstet Gynecol. 2010 Oct;116(4):815-8. PubMed

Nasal Bone

• First-trimester screening with nasal bone in twins.
  

  Cleary-Goldman J, Rebarber A, Krantz D, Hallahan T, Saltzman D. Am J Obstet Gynecol. 2008 Sep;199(3):283.e1-3. PubMed

• First-trimester screening for trisomy-21 using a simplified method to assess the presence or absence of the fetal nasal bone.
  

  Orlandi F, Rossi C, Orlandi E, Jakil MC, Hallahan TW, Macri VJ, Krantz DA. Am J Obstet Gynecol. 2005 Apr;192(4):1107-11.

• Measurement of nasal bone length at 11-14 weeks of pregnancy and its potential role in Down syndrome risk assessment.
  

  Orlandi F, Bilardo CM, Campogrande M, Krantz D, Hallahan T, Rossi C, Viora E. Ultrasound Obstet Gynecol. 2003 Jul;22(1):36-9. PubMed

Adverse Outcomes

• First-trimester maternal dried blood Down syndrome screening marker levels in early pregnancy loss.
  

  Krantz D, Hallahan T, Ishack S, Macri VJ, Macri JN. Prenat Diagn. 2006 Dec;26(12):1137-41. PubMed

• First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
  

  Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW, Silver R, Pergament E, Platt LD, Filkins K, Johnson A, Mahoney M, Hogge WA, Wilson RD, Mohide P, Hershey D, Wapner R. Am J Obstet Gynecol. 2004 Oct;191(4):1452-8. PubMed

• Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss.
  

  Goetzl L, Krantz D, Simpson JL, Silver RK, Zachary JM, Pergament E, Platt LD, Mahoney MJ, Wapner RJ. . Obstet Gynecol. 2004 Jul;104(1):30-6. PubMed

• First-trimester pregnancy-associated plasma protein-A and Cornelia de Lange syndrome.
  

  Arbuzova S, Nikolenko M, Krantz D, Hallahan T, Macri J. . Prenat Diagn. 2003 Oct;23(10):864. PubMed

• Frequency and clinical consequences of extremely high maternal serum PAPP-A levels.
  

  Cuckle H, Arbuzova S, Spencer K, Crossley J, Barkai G, Krantz D, Muller F, Nikolenko M, Aitken D, Hallahan T, Macri J, Buchanan PD. Prenat Diagn. 2003 May;23(5):385-8. PubMed

• Second-trimester pregnancy associated plasma protein-A levels are reduced in Cornelia de Lange syndrome pregnancies.
  

  Aitken DA, Ireland M, Berry E, Crossley JA, Macri JN, Burn J, Connor JM. Prenat Diagn. 1999 Aug;19(8):706-10. PubMed

Second Trimester Down Syndrome Screening

• Free beta hCG screening of hydropic and non-hydropic Turner syndrome pregnancies.
  

  Laundon CH, Spencer K, Macri JN, Anderson RW, Buchanan PD. Prenat Diagn. 1996 Sep;16(9):853-6. PubMed

• Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
  

  Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, Groome NP, Macri JN, Connor JM. N Engl J Med. 1996 May 9;334(19):1231-6. PubMed

• Toward the optimal protocol for Down syndrome screening.
  

  Macri JN, Spencer K. Am J Obstet Gynecol. 1996 May;174(5):1668-9. PubMed

• Prenatal maternal dried blood screening with alpha-fetoprotein and free beta-human chorionic gonadotropin for open neural tube defect and Down syndrome.
  

  Macri JN, Anderson RW, Krantz DA, Larsen JW, Buchanan PD. Am J Obstet Gynecol. 1996 Feb;174(2):566-72. PubMed

• Enhanced twin pregnancy detection within an open neural tube defect and Down syndrome screening protocol using free-beta hCG and AFP.
  

  Barnabei VM, Krantz DA, Macri JN, Larsen JW Jr. Diagn. 1995 Dec;15(12):1131-4. PubMed

• Maternal serum free beta hCG screening: results of studies including 480 cases of Down syndrome.
  

  Macri JN, Spencer K, Garver K, Buchanan PD, Say B, Carpenter NJ, Muller F, Boué A. Prenat Diagn. 1994 Feb;14(2):97-103. PubMed

• Prenatal screening for trisomy 18 with free beta human chorionic gonadotrophin as a marker.
  

  Spencer K, Mallard AS, Coombes EJ, Macri JN. BMJ. 1993 Dec 4;307(6917):1455-8. PubMed

• Dual analyte immunoassay in neural tube defect and Down's syndrome screening: results of a multicentre clinical trial.
  

  Spencer K, Macri JN, Anderson RW, Aitken DA, Berry E, Crossley JA, Wood PJ, Coombes EJ, Stroud M, Worthington DJ, et al. Ann Clin Biochem. 1993 Jul;30 ( Pt 4):394-401. PubMed

• Antenatal screening for Down's syndrome.
  

  Spencer K, Macri JN, Coombes EJ, Ward AM. BMJ. 1993 Jun 12;306(6892):1616. Erratum in: BMJ 1993 Jun 19;306(6893):1692.

• Dual Analyte immunoassay--a new approach to neural tube defect and Down's syndrome screening.
  

  Macri JN, Spencer K, Anderson R. . Ann Clin Biochem. 1992 Jul;29 ( Pt 4):390-6. PubMed

• Early detection of Down's syndrome using free beta human choriogonadotropin.
  

  Spencer K, Macri JN. Ann Clin Biochem. 1992 May;29 ( Pt 3):349-50. PubMed

• Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age.
  

  Macri JN, Kasturi RV, Krantz DA, Cook EJ. Obstet Gynecol. 1991 Jun;77(6):963-5. PubMed

• Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin.
  

  Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND, Young JA, Romero K, Larsen JW Jr. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1248-53. PubMed

• Measurement of unconjugated estriol by enzyme-linked immunosorbent assay fails to show an association with Down syndrome.
  

  Marci JN, Krantz DA, Kasturi RV, Cook EJ, Larsen JW. Am J Obstet Gynecol. 1990 Jun;162(6):1634-5. PubMed

• Maternal serum Down syndrome screening: unconjugated estriol is not useful.
  

  Macri JN, Kasturi RV, Krantz DA, Cook EJ, Sunderji SG, Larsen JW. Am J Obstet Gynecol. 1990 Mar;162(3):672-3. PubMed

• Low alpha-fetoprotein and trisomy.
  

  Macri JN, Buchanan PD, Gold MP. Lancet. 1986 Aug 16;2(8503):405. PubMed

• An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities.
  

  Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. Am J Obstet Gynecol. 1984 Apr 1;148(7):886-94. PubMed

Open Neural Tube Defect Screening

• Screening for open neural tube defects.
  

  Krantz DA, Hallahan TW, Sherwin JE. Clin Lab Med. 2010 Sep;30(3):721-5. Epub 2010 Jun 15. Review. PubMed

• Pitfalls in evaluating black gravid women.
  

  Macri JN, Kasturi RV, Hu MG, Krantz DA, Douros TJ, Sajda P, Cook EJ. Am J Obstet Gynecol. 1987 Oct;157(4 Pt 1):820-2. PubMed

• Maternal serum alpha-fetoprotein screening, maternal weight, and detection efficiency.
  

  Macri JN, Kasturi RV, Krantz DA, Koch KE. Am J Obstet Gynecol. 1986 Oct;155(4):758-60. PubMed

• Critical issues in prenatal maternal serum alpha-fetoprotein screening for genetic anomalies.
  

  Macri JN. Am J Obstet Gynecol. 1986 Aug;155(2):240-6. PubMed

• Results and benefits of a maternal serum alpha-fetoprotein screening program.
  

  Macri JN. . JAMA. 1985 Apr 26;253(16):2364-6. PubMed

Free Beta hCG Biochemistry

• Stability of intact chorionic gonadotropin (hCG) in serum, liquid whole blood, and dried whole-blood filter-paper spots: impact on screening for Down syndrome by measurement of free beta-hCG subunit.
  

  Spencer K, Macri JN, Carpenter P, Anderson R, Krantz DA. Clin Chem. 1993 Jun;39(6):1064-8. PubMed

• Free beta-chorionic gonadotropin: a cross-reactivity study of two immunometric assays used in prenatal maternal serum screening for Down's syndrome.
  

  Macri JN, Spencer K, Anderson RW, Cook EJ. Ann Clin Biochem. 1993 Jan;30 ( Pt 1):94-8. PubMed

Sequential testing

• First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Sequential pathways of testing after first-trimester screening for trisomy 21.
  

  Platt LD, Greene N, Johnson A, Zachary J, Thom E, Krantz D, Simpson JL, Silver RK, Snijders RJ, Goetzl L, Pergament E, Filkins K, Mahoney MJ, Hogge WA, Wilson RD, Mohide P, Hershey D, MacGregor S, Bahado-Singh R, Jackson LG, Wapner R; Obstet Gynecol. 2004 Oct;104(4):661-6. PubMed

• Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters.
  

  Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. Br J Obstet Gynaecol. 1997 Jul;104(7):811-7. PubMed

Risks and Statistics

• Statistical flaw in SURUSS model. Prenat Diagn. 2004 Sep;24(9):753-4.
  

  Krantz DA, Hallahan TW, James Macri V, Macri JN.

• Serum alpha-fetoprotein (MSAFP) patient-specific risk reporting: its use and misuse.
  

  Macri JN, Kasturi RV, Krantz DA, Cook EJ, Larsen JW. Am J Hum Genet. 1990 Mar;46(3):587-90. PubMed

• Variability in MSAFP predicted rates of Down syndrome.
  

  Macri JN, Krantz DA, Cook EJ, Sorensen K, Kasturi RV. Am J Hum Genet. 1989 Feb;44(2):296-7. PubMed

• Maternal serum alpha-fetoprotein screening. II. Pitfalls in low-volume decentralized laboratory performance.
  

  Macri JN, Kasturi RV, Krantz DA, Hu MG. Am J Obstet Gynecol. 1987 Mar;156(3):533-5.

Ultrasound Markers for Down Syndrome Screening

• Are second-trimester minor sonographic markers for Down syndrome useful in patients who have undergone first-trimester combined screening?
  

  Sood M, Rochelson B, Krantz D, Ravens R, Tam Tam H, Vohra N, Lewis D, Ray B. Am J Obstet Gynecol. 2010 Oct;203(4):408.e1-4. Epub 2010 Jul 14. PubMed

• Genetic sonography after first-trimester Down syndrome screening.
  

  Krantz DA, Hallahan TW, Macri VJ, Macri JN. Ultrasound Obstet Gynecol. 2007 Jun;29(6):666-70. PubMed

• Geometric morphometric analysis of shape outlines of the normal and abnormal fetal skull using three-dimensional sonographic multiplanar display.
  

  Rochelson B, Vohra N, Krantz D, Macri VJ. Ultrasound Obstet Gynecol. 2006 Feb;27(2):167-72. PubMed

Screening with Urine Markers

• Comparison of urinary free beta (hCG) and beta-core (hCG) in prenatal screening for chromosomal abnormalities.
  

  Hallahan TW, Krantz DA, Tului L, Alberti E, Buchanan PD, Orlandi F, Klein V, Larsen JW Jr, Macri JN. Prenat Diagn. 1998 Sep;18(9):893-900. PubMed

• Urine free beta hCG and beta core in pregnancies affected by Down's syndrome.
  

  Spencer K, Aitken DA, Macri JN, Buchanan PD. Prenat Diagn. 1996 Jul;16(7):605-13. PubMed